Ehimen C. Aneni

Ehimen C. Aneni

Auto-generated profile, based on publicly available information

Ehimen C. Aneni

Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2017 in Vascular Medicine
Verified
Journal Article
Open access
COChukwuemeka U Osondu
Chukwuemeka U Osondu
BVBryan Vo
Bryan Vo
EOEbenezer T Oni
Ebenezer T Oni
MBMichael J Blaha
Michael J Blaha
EVEmir Veledar
Emir Veledar
EAEhimen C Aneni
Ehimen C Aneni
Erectile dysfunction (ED) is associated with cardiovascular disease (CVD) and CVD mortality. However, the relationship between ED and subclinical CVD is less clear. We synthesized the available data on the association of ED and measures of subclinical CVD. We searched multiple databases for published literature on studies examining the association of ED and measures of subclinical CVD across four domains: endothelial dysfunction measured by flow-mediated dilation (FMD), carotid intima–media thickness (cIMT), coronary artery calcification (CAC), and other measures of vascular function such as the ankle–brachial index, toe–brachial index, and pulse wave velocity. We conducted random effects meta-analysis and meta-regression on studies that examined an ED relationship with FMD (15 studies; 2025 participants) and cIMT (12 studies; 1264 participants). ED was associated with a 2.64 percentage-point reduction in FMD compared to those without ED (95% CI: –3.12, −2.15). Persons with ED also had a 0.09-mm (95% CI: 0.06, 0.12) higher cIMT than those without ED. In subgroup meta-analyses, the mean age of the study population, study quality, ED assessment questionnaire (IIEF-5 or IIEF-15), or the publication date did not significantly affect the relationship between ED and cIMT or between ED and FMD. The results for the association of ED and CAC were inconclusive. In conclusion, this study confirms an association between ED and subclinical CVD and may shed additional light on the shared mechanisms between ED and CVD, underscoring the importance of aggressive CVD risk assessment and management in persons with ED.

1 December 2019 in Preventive Medicine
Verified
Journal Article
Closed access
JVJavier Valero-Elizondo
Javier Valero-Elizondo
EAEhimen C. Aneni
Ehimen C. Aneni
COChukwuemeka U. Osondu
Chukwuemeka U. Osondu
GGGowtham R. Grandhi
Gowtham R. Grandhi
SVSalim S. Virani
Salim S. Virani
KNKhurram Nasir
Khurram Nasir

1 December 2020 in American Journal of Preventive Cardiology
Verified
Journal Article
Open access
EAEhimen C. Aneni
Ehimen C. Aneni
MBMarcio Sommer Bittencourt
Marcio Sommer Bittencourt
CTCatherine Teng
Catherine Teng
MCMiguel Cainzos-Achirica
Miguel Cainzos-Achirica
COChukwuemeka U. Osondu
Chukwuemeka U. Osondu
KNKhurram Nasir
Khurram Nasir
Recent studies suggest that non-alcoholic fatty liver disease (NAFLD) in lean (BMI<25 ​kg/m2) individuals presents a distinct phenotype. We sought to determine the cardiometabolic consequences of lean NAFLD in a population cohort of relatively young asymptomatic individuals who participated in a voluntary routine health promotion evaluation in Brazil. We analyzed data in our population collected from 2004 to 2016. Medical and demographic history, anthropometric measures, and fasting blood samples were obtained. Participants had ultrasonography to assess for fatty liver. We defined NAFLD as fatty liver in individuals scoring below 8 on the alcohol use disorders identification test (AUDIT). We included data from 9137 individuals who had complete data at baseline and at follow-up. The prevalence of lean NAFLD in our cohort was 3.8%. Over the median follow-up period of 2.4 years (range 0.5–9.9 years), lean individuals had 74% (HR: 1.74 (1.39–2.18)) and 67% (1.67 (1.29–2.15)) greater risk of developing elevated BP and elevated glucose, and nearly 3 times the risk of atherogenic dyslipidemia (HR: 2.98 (2.10–4.24)) compared to lean individuals without NAFLD. Lean NAFLD individuals also had higher risk of developing elevated glucose (HR: 1.37 (1.07–1.75)) and atherogenic dyslipidemia (1.46 (1.05–2.01)) compared to non-lean individuals without NAFLD. However, there was no significant difference in the risk of elevated BP, elevated glucose or atherogenic dyslipidemia between lean NAFLD and non-lean individuals with NAFLD in fully adjusted models. Lean NAFLD is not metabolically benign. Further cardiovascular risk stratification and appropriate preventive measures should be considered in lean individuals who present with NAFLD.

15 October 2022 in International Journal of Stroke
Verified
Journal Article
Closed access
NKNavreet Kaur
Navreet Kaur
SPSmit Patel
Smit Patel
MAMichael Omoniyi Ayanbadejo
Michael Omoniyi Ayanbadejo
HHHaydn Hoffman
Haydn Hoffman
EAEmmanuel Akano
Emmanuel Akano
FOFadar Oliver Otite
Fadar Oliver Otite
Objectives: To evaluate current trends in the utilization of intravenous thrombolysis (IV-tPA) and mechanical thrombectomy (MT) in acute ischemic stroke (AIS) in various age groups of children in the United States. Methods: We conducted a serial cross-sectional study using primary AIS admissions in children ⩽ 17 years (weighted n = 2807) contained in the 2009–2019 KIDS Inpatient Database. Age-specific utilization frequency of IV-tPA and MT were calculated. Multivariable-adjusted models were used to evaluate demographic predictors of treatment. Results: From 2009 to 2019, there were 2807 AIS admissions in children in the KID of which 55.9% were in boys and 29.9% were 15–17 years old.128 (4.6%) received IV-tPA. IV-tPA utilization differed by age (5–9 years: 3.1%, 15–17 years 8.1% p value < 0.001). Overall MT usage was 2.3% and this also varied by age (1–4 years: 0.9% and 15–17years 4.0%, p value = 0.006). IV-tPA utilization almost tripled across the study period (2.5% 2009 to 6.5% in 2019, p value = 0.001) while MT use more than doubled over time (1.2% in 2009 and 3.0% in 2019, p value = 0.048). Increased IV-tPA utilization was seen primarily in children 10–14 years (0.8% in 2009 to 7.2% 2019, p value = 0.005) and 15–17 years (5.4% in 2009 to 10.4% in 2019, p value = 0.045). Utilization in younger age groups remained unchanged over time. MT usage was very variable across various age groups over time. IV-tPA and MT utilization increased over time in nonchildren’s hospitals (both p values < 0.05) but usage in designated children’s hospitals did not change significantly over time. In multivariable models, there was no significant difference in odds of IV-tPA and MT use by sex, race or insurance status. Conclusion: IV-tPA and MT utilization in pediatric AIS increased in the United States over the past decade mainly in older children 10–17 years. Utilization increased mainly in patients hospitalized in nonchildren’s hospitals. Usage in children’s hospitals did not change significantly over time.

6 April 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
EAEhimen C. Aneni
Ehimen C. Aneni
GSGul Jana Saeed
Gul Jana Saeed
MBMarcio Sommer Bittencourt
Marcio Sommer Bittencourt
MCMiguel Cainzos-Achirica
Miguel Cainzos-Achirica
COChukwuemeka U. Osondu
Chukwuemeka U. Osondu
KNKhurram Nasir
Khurram Nasir
Background: There is limited knowledge about the risk of non-alcoholic fatty liver disease (NAFLD) associated with cardiometabolic disorders in lean persons. This study examines the contribution of cardiometabolic disorders to NAFLD risk among lean individuals and compares to non-lean individuals.Methods: We analyzed longitudinal data from 6,513 participants of a yearly voluntary routine health testing conducted at the Hospital Israelita Albert Einstein, Brazil. NAFLD was defined as hepatic ultrasound diagnosed fatty liver in individuals scoring below 8 on the alcohol use disorders identification test. Our main exposure variables were elevated blood glucose, elevated blood pressure (BP), presence of atherogenic dyslipidemia (AD, defined as the combination of elevated triglycerides and low HDL cholesterol) and physical inactivity (<150 minutes/week of moderate activity). We further assessed the risk of NAFLD with elevations in waist circumference and high sensitivity C-reactive protein (HsCRP).Results: Over 15,580 person-years (PY) of follow-up, the incidence rate of NAFLD was 7.7 per 100 PY. In multivariate analysis adjusting for likely confounders, AD was associated with a 72% greater risk of NAFLD (IRR: 1.72 [95% CI:1.32–2.23]). Elevated blood glucose (IRR: 1.71 [95%CI: 1.29–2.28]) and physical inactivity (IRR: 1.46 [95%CI: 1.28–1.66]) were also independently associated with increased risk of NAFLD. In lean individuals, AD, elevated blood glucose and elevated BP were significantly associated with NAFLD although for elevated blood glucose, statistical significance was lost after adjusting for possible confounders. Physical inactivity and elevations in HsCRP were not associated with the risk of NAFLD in lean individuals only. Among lean (and non-lean) individuals, there was an independent association between progressively increasing waist circumference and NAFLD.Conclusion: Cardiometabolic risk factors are independently associated with NAFLD. However, there are significant differences in the metabolic risk predictors of NAFLD between lean and non-lean individuals. Personalized cardiovascular disease risk stratification and appropriate preventive measures should be considered in both lean and non-lean individuals to prevent the development of NAFLD.

9 September 2025 in Neurology
Verified
Journal Article
Closed access
RMRonald Miller
Ronald Miller
NANnabuchi Anikpezie
Nnabuchi Anikpezie
HHHaydn Hoffman
Haydn Hoffman
ABAbdulaziz T. Bako
Abdulaziz T. Bako
SPSmit Patel
Smit Patel
FOFadar O. Otite
Fadar O. Otite
There is paucity of data on the population-level incidence of moyamoya angiopathy (MMA) in the United States. The aim of this study was to estimate sex-specific, age-specific, and race-specific incidence of MMA in the United States over the period 2011-2020. We used the State Ambulatory Surgery, Emergency, and Inpatient Databases of Florida (2005-2020), Georgia (2010-2020), Maryland (2012-2020), and New York (2005-2020) to conduct a retrospective study. We validated ICD-10 codes for MMA in a single academic center in the United States and used primary and secondary ICD-9/10 discharge codes to identify all new cases of MMA in these 4 states from 2011 to 2020. Incident MMA counts were combined with census data to compute incidence separately for moyamoya disease (MMD) and moyamoya syndrome (MMS). Multivariable-adjusted Poisson regression models were used to compare MMA incidence between demographic subgroups, and joinpoint regression was used to evaluate trends over time. Among 24,614 MMA hospitalizations over the study period, 4,192 incident cases were identified from 2011 to 2020. The median age at hospitalization was 41.0 years (interquartile range 24.0-54.0), and 67.9% of admissions were in women. The overall age-standardized and sex-standardized incidence of MMA was 0.75 (95% CI 0.73-0.77) cases/100,000/year. The incidence of isolated MMD was 0.57 (95% CI 0.54-0.59), whereas that of MMS was 0.18 (95% CI 0.16-0.20). MMD incidence increased with age, up to 45-64 years (trend p value = 0.041), whereas that of MMS declined with age (trend p value <0.001). Following multivariable Poisson regression, the overall MMA incidence in women was approximately 2 times that in men (adjusted incidence rate ratio [aIRR] 1.97, 95% CI 1.69-2.30). Incidence was higher in Asian (aIRR 2.46, 95% CI 1.88-3.23) and Black (aIRR 2.58, 95% CI 2.17-3.07) individuals compared with non-Hispanic White individuals. Incidence increased over time (annualized percentage change 7.7%, 95% CI 5.3%-10.5%), with most of this increase occurring in individuals aged 45-64 years and 65 years or older. The incidence of MMA in the United States is higher than previously believed. Overall incidence in Black individuals is just as high as that in Asian individuals, and both are higher than that of non-Hispanic White individuals. Further studies are needed to understand the genetic and environmental factors contributing to race/ethnic disparities in MMA incidence in the United States.